METALLO-FULLERENOLS AND ITS APPLICATION IN PREPARATION OF MEDICINES FOR INHIBITING THE GROWTH OF TUMOUR

Description

Field of the Invention

[0001] The present invention is directed to the use ofmultihydroxylated metallofullerols for low-toxic and high-efficient anticancer medicines. Note that the term "metallofullerols" used in this document means the polyhydroxylated metallofullerene and polyhydroxylated metallofullerene compound.

Background of the Invention

[0002] Malignant tumor is the important diseases threatened the human health, which is becoming the major reason of death. In China, liver cancer, gastric cancer and breast cancer are the highest incidence of tumor among them. Now, there are about 7.0 million deaths and 24.6 million persons alive with cancer (within three years of diagnosis) in the world, while, there are about 1.3 million deaths in China. Beside the death, cancer has brought a big burden to family and society. In fact, most of the current tumor-chemotherapeutic agents, such as, Epirubicin, Cyclophusphamide, Cisplatin, and Pacilitaxel, are highly efficient, but their therapeutic efficiency is vitally lowered by the side-effects of the drug that limits the clinic dosage and effective concentrations of therapeutic agents to tumor. To dissolve this issue, new types of drug with high antineoplastic efficiency and nearly without toxicity need to develop imperatively.

[0003] As one of potential solutions to this issue, the use of nanoparticles for tumor therapy is intriguingly interesting. To realize the high efficiency and low toxicity, a potential and promising direction is to ingeniously utilize the nanoparticles whose surfaces can be adequately modified to meet the specific expectation of tumor therapy. Some nanoscale targeted-delivery devices, quantum-dots for high sensitivity examination of diseases, medical imaging and other nanoparticles, can be targeted to cancer cells. This may allow for smaller doses of toxic substances as the drugs are delivered directly to the target tissue, which has become the frontier issues.

[0004] Although fullerene (C60), an inner-hollow, geodesic-sphere shaped molecule was first discovered in 1985 (Kroto, et al. Nature, Vol. 318, p. 162, 1985), its application in life science is limited because of very low solubility in water which leads to a low biocompatibility in living organisms. This molecule was later named buckminster fullerene in honor of Buckminster Fuller, the inventor of the geodesic dome. Typically, fullerenes each have 12 pentagons, and 20 hexagons and is classified as an icosahedron, the highest symmetry structure possible. Recent studies indicate that the properties of fullerenol molecules largely depend on the structures of the hydroxyl number and their outer modified groups (Sayes CM et al, Nano Lett, 2004, 4(10):1881-1887; Dugan L et al, Proc Natl Acad Sci USA 1997, 94: 9434-9439; Mirkova SM et al, Nitric Oxide 2004, 11:201-207; Chiang LY et al, J Org Chem 1994, 59, 3960-3968). The lethal dose of fullerene decreased over 7 orders of magnitude with relatively minor alterations in such a surface modification (Sayes 2004). The LD50 of C60(OH)₂₄ is more than 5,000 ppm, while the fullerene is 20 ppb. Using C14-labelled fullerene derivative, Nakamura (1994) found it can be distributed to different tissues and organs quickly and most was enriched in liver tissue. ¹⁶⁶HO@C₈₂(OH)_y could be recognized by reticuloendothelial cells and distributed to various tissues and organs except brain and fat quickly in 1 h after tail-vein injection in SD rats models (Cagle DW et al., Proc Natl Acad Sci 1999, 96:5182-5187), the concentration in each tissue was in the order of liver, bone, spleen, kidney and lung.

[0005] But in fullerene family, there are another large number of members, the atom-endohedral fullerenes. When metal(s) are encaged by the fullerene cage consisting of different carbon atoms like C60, C82, etc., it is called endohedral metallofullerene, including Sc, Y, Ca, Sr, Na, K, Ba, Li, Cs, Zr, Hf. The geometric and electronic structures of endohedral metallofullerene and their physiochemical properties are quite different from the hollow fullerene like C60, which have the potential for the application in multiple fields as organic magnet, non-linear optic materials, functional molecular switch, MRI imaging, biological isotope labeling ans so on (Bolskar RD et al., J Am Chem Soc 2003; 125:5471-5478).

[0006] The metallofullerenol molecule (e.g., Gd@C₈₂(OH)_x) has a definite nanostructure and nanosize, and can be well characterized. In aqueous solutions, Gd@C₈₂(OH)_x does not exist as an individual molecule or molecular ion but congregates into nanoparticles through large molecular interactions. These nanoparticles consist of several tens molecules whose basis is a magnetic core (Gd) and a closed carbon nano-sheath with surface modifications of hydroxyl groups (OH). Further, the outer surface of the nanoparticle is usually embraced with water molecules through hydrogen bonds, which leads the nanoparticles to have a good biocompatibility in vivo.

[0007] JP 2001 114713 discloses metallofullerenols of general formula Gd_x@C_y(OH)_z wherein x is 1 or 2, y is 60 or even number between 70 and 120 and z in an integer more than 30, and an MRI contrast agent comprising dais metallofullerenols. Sitharaman B et al., Nano Letters, American Chemican Society, 2004, vol. 4, n° 12 discloses two water-soluble gadofullerenol species useful as MRI contrast agents, among which Gd@C₆₀(OH)x. Kato et al., Journal of the American Chemical Society, 2003, Vol. 125, n° 14 discloses water-soluble multi-hydroxyl lanthanoid endohedral metallofullerenes M@C_R2(OH)" and the uses thereof as MRI contrast agents.

[0008] Currently, cancer fighting drugs are toxic to both tumor and normal cells, thus the efficacy of chemotherapy is often limited. This invention describes that the outer surface of the endohedral metallofullerenes nanoparticles is usually embraced with water molecules through hydrogen bonds, which leads the nanoparticles to have a good biocompatibility in vivo. Furthermore, these hydrolated endohedral metallofullerenes have been found to have ability for the inhibition of the growth of tumor. The results suggest that fullerene derivatives with proper surface modifications and sizes may help realize the dream of tumor chemotherapeutics of high-efficacy and low-toxicity.

Summary of the Invention

[0009] It is known that tumor tissues have more vessels than normal ones and there are number of pores at nano-size on the tumor microvascular wall, which is important for nutrient and oxygen exchange of tumor tissue from outside. If these types of pores are blocked by the similar size of nanoparticles, the blood circulation would be jammed. Thus, cancerous tissues cannot obtain enough nutrient and further stop the growth of tumor cells. To confirm this point, the inventor designed metallofullerol compound. Its molecular size is about 1 nm. This compound has the high anti-tumor efficiency, whereas it can be aggregated and formed 1-200 nm nanoparticles at suitable sizes with a good biocompatibility. The antitumor mechanism of these nanoparticles is not due to toxic effects to cells because they do not directly kill the tumor cells, more possibly, due to jamming the pore of tumor microvessels.

[0010] This invention provides metallofullerols and a composition comprising metallofullerols for use in inhibition of tumor growth.

[0011] This invention provides a composition of antitumor pharmaceutical, which includes metallofullerol nanoparticles and acceptable carrier for medicine.

[0012] This invention also provides the use of metallofullerols in the preparation of antitumor drugs.

[0013] To achieve the objection, this invention includes metallofullerols for use in inhibition of tumor growth, represented by the general formula (I)

        M@C_2m(OH)_x     (I)

wherein M is a rare earth metal of La or Gd; m is 41 or 30; x is from 10 to 50.

[0014] This material is comprised of a metal atom incorporated into inside of its shell structure and an ordinary fullerene cage composed of carbon, while its surface is modified with many hydroxyl groups (OH) (Figure 1). Thus, M@C_2m(OH)_x have showed have a good biocompatibility in vivo. At the mean time, due to the existence of hydroxyl groups, metallofullerol has the lower toxicity than its form as metallofullerene.

[0015] Actually, due to the reset of the neighboring hydroxyl, the numbers of O and H in Carbon cage are different, formula are thus written as M@C_2mO_xH_y.

        M@C_2mO_xH_y     (2)

[0016] The metallofullerols with general formula aggregate and form nanoparticles, comprising formula [M@C_2m(OH)_x]_n.

[0017] In one aspect, the invention provides a composition for use in inhibition of tumor growth comprising the metallofullerol nanoparticles with general formula [M@C_2m(OH)_x]_n, wherein M is selected from a rare earth metal of La or Gd, m=41 or 30 and 10≤x≤50, n is the number of molecules of the metallofullerenols from which the metallofullerenols nanoparticles is formed by agglomeration, 1 ≤n≤200.

[0018] Through the selection of proper solvent, the suitable concentration, sonication and so on, the size of aggregated particles of metallofullerol (M@C_2m(OH)_x) can be controlled within 1-200 nm.

[0019] In one embodiment, the composition of the invention also provides a mixture comprising proper solvent and/or medicine-compatible carrier. The solvent consists of water, physiological saline, Tris-HCl or phosphate buffer. The above-mentioned medicine-compatible carrier is the acceptable and conventional carriers in medical science, i.e., thinner, excipient, filler, sorbent, accelerant and so on.

[0020] In a particular embodiment, the composition of this invention includes the concentration of metallofullerols within 1x10^-5-1mmol/L. When the concentration is more than 1mmol/L, the solubility of metallofullerols decrease and larger size particles will be easily formed. The final concentration of metallofullerols within 1x10^-5-1 mmol/L has no obvious cytotoxicity.

[0021] In another particular embodiment, the metallofullerols or the composition for use in inhibition of tumor growth are characterized in that said tumor comprises but not limits to lung cancer, liver cancer, gastric cancer, esophageal cancer, colorectal carcinoma, bladder cancer, breast cancer, cervical cancer, ovary cancer, human osteosarcoma, angiosarcoma, lymphosarcoma, leucocythemia, melanoma, and skin cancer.

[0022] A polyhydroxylated endohedral metallofullerene compounds is prepared and used for the inhibition of the tumor growth. The compound comprises a general formula, [M@C_2m(OH)_x]_n, wherein, M is a rare earth metal of La or Gd, m=41 or 30 and 10≤x<50. In one other aspect, the invention is related to the use of a metallofullerol in the preparation of tumor-inhibiting medicine, characterized in that said metallofullerol is represented by general formula M@C_2m(OH)_x, wherein M is a rare earth metal of La or Gd, m=41 or 30 and 10≤x<50.

[0023] In another aspect, the invention provides the use of a composition in the preparation of tumor-inhibiting medicine, characterized in that it comprises the metallofullerols nanoparticles represented by [M@C_2m(OH)_x]_n, wherein M is a rare earth metal of La or Gd, m=41 or 30 and 10≤x<50, n is the number of molecules of the metallofullerols from which the metallofullerols nanoparticles are formed by agglomeration, 1≤n<200.

[0024] These tumor-inhibiting medicines are available either in liquid or in lyophilized form. The medicines are made into different dosage forms, and dose of the metallofullerenols is 5x10^-8-1x10^-2 mmol/kg/day for clinical, which is derived from dosage of 1x10^-6-2x10^-1mmol/kg/day for pharmacological study on mice.

[0025] The tumor-inhibiting medicines are made into different dosage forms, and dose of the metallofullerenols is 5x10^-6-1.25x10^-4 mmol/kg/day for clinical, which is derived from dosage of 1x10^-4-2.5x10^-3 mmol/kg/day for pharmacological study on mice.

[0026] The antitumor composition and tumor-inhibiting medicines of the invention can be used to patients through venous injection, peritoneal injection, oral administration or local drug delivery. In one preferable example of this invention, the above-mentioned composition or medicines was prepared as a solution for injection.

[0027] Comparing to the clinical anticancer drugs such as Pacolitaxel, Cyclophosphamide, and Cisplatin, metallofullerol of M@C_2m(OH)_x or M@C_2mO_xH_y has superior advantages of higher antitumor efficiency, low dosage, low toxicity, and better biocompatibility.

Brief Description of the Figures

[0028] Various embodiments of the invention are described with reference to the figures, which are provided for the purpose of illustration only and are not intended to be limiting of the invention, the full scope of which is set forth in the claims below.

Figure 1 is the schematic draw of the M@C_2m(OH)_x molecule. The purple atom in the cage represents metal. The red atom out the cage represents oxygen, while the white one for hydrogen.

Figure 2 is the HPLC chromatogram for Gd@C_2m (in 5PBB columns)

Figure 3 is X-ray photoemission spectra for Gd@C₈₂(OH)₂₂ (a) and Gd@C₈₂(OH)₁₂ (b).

Figure 4 is the high resolution atomic force microscopic image of [Gd@C₈₂(OH)₂₂]_n nanoparticles in solution.

Figure 5 is the inhibition curve of H22 hepatoma growth by treatment with [Gd@C₈₂(OH)₂₂]_n nanoparticles at a lower dose.

Figure 6 is the inhibition curve of H22 hepatoma growth by treatment with [Gd@C₈₂(OH)₂₂]_n nanoparticles at a higher dose.

Figure 7 is the dose-dependent inhibition efficiency of CTX on murine H22 tumor growth.

Figure 8 is the dose-dependent inhibition efficiency of [Gd@C₈₂(OH)_x]_y on murine H22 tumor growth.

Figure 9 represents Hematoxylin-Eosin (HE) staining of the tumor tissues from the control (A and B), Gd@C82(OH)₂₂]_n-treated (C and D), and CTX-treated (E and F) mice.

Figure 10 is the inhibition curve of Lewis lung carcinoma growth by treatment with La@C₈₂(OH)₁₈.

Figure 11 shows the influence of Gd@C₈₂(OH)₂₂ on cell viability of HepG2.

Figure 12 shows the influence of Gd@C₈₂(OH)₂₂ on apoptosis of HepG2 cells.

Figure 13 shows the influence of Gd@C₈₂(OH)₂₆ on apoptosis of Rh35 cells.

Figure 14 shows the influence of Gd@C₈₂(OH)₃₂ on apoptosis of MCF-7 cells.

Figure 15 shows the influence of La@C₈₂(OH)₂₀ on cell viability of neuro-glioma cells.

Detailed Description of the Invention

[0029] In this application, metallofullerenes of Gd@C₈₂(OH)_x, Gd@C₆₀(OH)_x, La@C₈₂(OH)_x, La@C₆₀(OH)_x are synthesized using arc discharge method and extracted using a high-temperature and high-pressure method, the preparation method referred China Patent No. 03146028.3. The synthesis and purification of Gd@C₆₀ cited Robert D. Bolskar et al (J. AM. CHEM. SOC. 2003, 125, 5471-5478.)

[0030] In one or more embodiments, M@C_2m(OH)_x prepared according to this method, the number of the hydroxyl group is within 10 to 50, which can be determined by the concentrations of NaOH. Thus, the hydroxyl group can be controlled according to the modulation of the concentrations of NaOH. However, when x is below 10, the biocompatibility is not good. When x is more than 50, the C₈₂ or C₆₀ cage is not stable.

[0031] The hydroxyl number is crucial for its solubility in water-based solution and for clinical application, a further measurement of the hydroxyl number is performed using X-ray photoemission spectroscopy (XPS) and Synchrotron Radiation based XPS in Beijing.

[0032] The samples used in XPS experiment are deposited onto the high-purity golden substrates to obtain thin films for the XPS measurements, which is carried out at ultra vacuum chamber with background pressure of 8x10^-10 Torr, and about 1x10^-9 Torr during the measurement. The photon from synchrotron radiation was used as the excitation source. The experimental energy resolution was estimated to be about 0.5 eV To inspect the contamination, XPS survey scans on the surface were performed before and after measurements.

[0033] To make appropriate size of M@C_2m(OH)_x nanoparticles, Gd@C₈₂(OH)_x or Gd@C₆₀(OH)_x is first dissolved in physiological saline solution and sonicated for 1min at room temperature. Then Gd@C₈₂OH₂₂ or Gd@C₆₀(OH)_x molecules will be aggregated into nanoparticles with diameters ranging from 1-200 nm. The following examples related to metallofullerol solutions use the metallofullerol nanoparticles within the size of 1-200 nm.

[0034] Below, various examples are listed to further elucidate the invention. But, this invention is not limited to the examples described as below.

Example 1

Synthesis and purification of Gd@C₈₂

[0035] The metallofullerenes are synthesized using arc discharge method and extracted using a high-temperature and high-pressure method. The starting materials are the mixture of Gd₂O₃ (purity >99.999%) powder and high purity graphite powder (purity>99.999%), its molar ratio is Gd : C = (0.5∼3) : 100. The mixture of powders is first pressed into a graphite rod which is sintered at 1000-2000 °C for 24 hours and used as the electrode in the arc discharge process. Another method is to make hole with a diameter of ∼ 20mm in the ready graphite rod and then fill the hole with Gd₂O₃ powders. This Gd₂O₃-filled graphite rod after being sintered can also used as the electrode in the arc discharge process. The soot of the are discharge process includes products like Gd@C_2m, Gd_2@C_2m, Gd@C_2n, C₆₀, C₇₀, etc as shown in Figure 2. In the syntheses processes, inert gas (like He or Ar) of 50∼600 torr is used, and the discharge current is 80∼500A.

Purification of Gd@C₈₂ and Gd@C₆₀

[0036] The soot is dissolved in toluene, and reflux in toluene at 100∼200°C for12∼24hours. Then, the products are extracted using a high-temperature and high-pressure method in DMF at 100∼200°C with 50∼100MPa, reflux for 12∼24 hours. Further separation and purification of Gd@C₈₂ and Gd@C₆₀ are performed using a two-step high performance liquid chromatography (HPLC, LC908-C60, Japan Analytical Industry Co) coupling with 5PBB and then Buckyprep columns (Nacalai Co. Japan). The isolated Gd@C₈₂ and Gd@C₆₀ species were identified by the matrix-assisted laser desorption time-of-flight mass spectrometer (MADLI-TOF-MS, AutoFlex, Bruker Co., Germany).

[0037] The purity of the final Gd@C₈₂ and Gd@C₆₀ product was greater than 99.5%. The production rate of Gd@C₈₂ is about 10% of the weight of graphite rods used, and Gd@C₆₀ is 35% of the weight of the graphite rods used.

Preparation and determination of Gd@C₈₁(OH)_x

[0038] The water-soluble Gd-fullerenols was synthesized by the alkaline reaction. The Gd@C₈₂ toluene solution (containing 1g Gd@C₈₂) was first mixed with 100 ml aqueous solution containing 50% NaOH, and then several drops of catalyst of 40 % TBAH (tetrabutylammonium hydroxide) were added into the reaction system. The mixture of solutions was vigorously stirred at room temperature; the color of the solution in beaker was changed from the originally deep violet into colorless, meanwhile a brown sludge precipitated onto bottom of the beaker. After adding more water into the brown sludge, it was stirring over night. The brown precipitate was washed using MeOH which was then removed by the vacuum-evaporation system. This washing manipulation was repeated several times for a complete removal of the remnant TBAH and NaOH. Finally, the brown precipitate was dissolved into deionized water with continuous stirring for 24 hrs until the solution colour became a clear reddish brown. Then it was purified by a Sephadex G-25 column chromatography (5x50 cm²) with an eluent of neutralized water. The remained trace catalyst and Na⁺ ions were completely removed in this process. To obtain a final Gd-metallofullerenol product of a narrow region of distribution of the hydroxyl number, the fraction (eluate) was collected in a time interval of only several minutes.

[0039] The elemental analysis method was first used to measure the number of hydroxyl groups, giving the hydroxyl number in different samples of Gd@C₈₂(OH)_n, collected at different retention time. We also tried to analyze Gd@C₈₂(OH)_n using MALDI-TOF-MS technique, but it is quite difficult to observe the mass peak of molecular ions, because under the laser interaction, the OH-group is easily dissociated from the cage surface. However the Gd@C₈₂ peaks exist in any case of analyses, indicating the high stability of this compound. This is a great merit for using it as a clinic medicine.

Preparation of Gd@C₆₀(OH)_x

[0040] The preparation of Gd@C₆₀(OH)_x is similar with the processes of Gd@C₈₂(OH)_x described above. After the separation process, the water-soluble products with purity >99.99% are freeze dryness and storage for the uses in anticancer experiments.

Synthesis of [Gd@C₈₂(OH)_x]_n and [Gd@C₆₀(OH)_x]_n (1≤n<200) nanoparticles

[0041] To make appropriate size of Gd@C₈₂(OH)_x or Gd@C₆₀(OH)_x nanoparticles, Gd@C₈₂(OH)_x or Gd@C₆₀(OH)_x is first dissolved in physiological saline solution and sonicated for 1min at room temperature. Then Gd@C₈₂OH₂₂ or Gd@C₆₀(OH)_x molecules will be aggregated into nanoparticles with diameters ranging from 1-200 nm.

Example 2

Determination of the number of hydroxyl group of Gd@C₈₂(OH)₂₂ and Gd@C₈₂(OH)₁₂

[0042] X-ray photoemission spectra for Gd@C₈₂(OH)₂₂ (a) and Gd@C₈₂(OH)₁₂ (b) are shown as Figure 3. The measurement of the hydroxyl number was performed using both commercial and synchrotron radiation X-ray photoemission spectroscopy. Through the binding energy spectra of C1s electrons for C=C and C-OH in Gd@C₈₂(OH)_x, intensities for the non-functionalized and hydroxylated carbons were obtained The hydroxyl number was hence calculated from the measured intensity ratio of sp² and hydroxylated carbons.

Example 3

Preparation of La@C_2m(OH)_x

[0043] Using the same method of Gd@C₈₂ for preparation of La@C₈₂ and La@C₆₀.

(1) Synthesis of metallofullerol La@C₈₂(OH)₁₈

[0044] Using NaOH alkaline method, in toluene, La@C₆₀ was reacted with 28% NaOH solution. After removing NaOH and other separation and purification procedures, the La@C₆₀(OH)₂₂ (with purity>99.9%) were obtained, which were lyophilized for use.

(2) Synthesis of metallofullerol La@C₆₀(OH)₂₂

[0045] Using NaOH alkaline method, in toluene, La@C₆₀ was reacted with 35% NaOH solution. After removing NaOH and other separation and purification procedures, the La@C₆₀(OH)₂₂ (with purity>99.9%) were obtained, which were lyophilized for use.

Example 4

Characterization of Nanoparticles

[0046] The size of M@C_2m(OH)_x molecule is about 1nm. However, in solution microenvironment, metallofullerol molecules are easily aggregated and formed 1-200 nm particles controlled by sonication.

[0047] The synchrotron radiation small-angle X-ray scattering (SR-SAXS), usually used for particles in the 0.5-150 nm size range, was employed to precisely determine the size of the [Gd@C₈₂(OH)₂₂]_n particles in saline solution. It is performed by focusing a low divergence X-ray beam onto a solution sample and observing a coherent scattering pattern that arises from electron density inhomogeneities in the saline solution of [Gd@C₈₂(OH)₂₂]_n. The average size of [Gd@C₈₂(OH)₂₂]_n particles in saline solution was determined to be 22.0 nm.

[0048] [Gd@C₈₂(OH)₂₂]_n particles dissolved into saline were measured by the high resolution Atomic Force Microscopy. The average size of the particles was 22.4 nm (ranging from 0-200 nm) in diameter (Figure 4). The two independent methods give the same results.

Example 5

[0049] 500 mg Gd@C₈₂OH₂₂ were dissolved in 400 ml physiological saline solution and sonicated for 1min at room temperature. Then they were divided into 100 ampoules for injection use.

Example 6

[0050] Antitumor studies of hydrolated metallofullerene nanoparticles were performed on Kunming mice (female, adult, 4 weeks at the start of the experiment, body weight ranging from 20 to 22 g). The mice were subcutaneously implanted with 1×10⁶ cells of H22 hepatoma (in 100 µl of saline) in each mouse at the right hind leg. Primary tumors (before administration of antitumor agents) were measured with calipers. The end point of the experiment was determined by the diameter of their leg loaded with tumor up to 2 or 2.2 centimeter. The size of tumor was monitored by daily measurement. Tumor growth curve was obtained by the diameter of the tumor as a function of the time.

[0051] The 40 mice of weight ranging from 20 to 22 g were randomly divided into 6 groups. The tumor-bearing mice were then systemically treated with hydrolated metallofullerene nanoparticles saline solution by intraperitoneal injections once a day. Two doses of hydrolated metallofullerene nanoparticles, 114 and 228 µg/kg corresponding to 1x10^-7 and 2x10^-7 mol/kg, respectively, were used in the experiment. The currently clinic antineoplastic agent CTX was used for the positive control, with a dose 30 mg/kg (1x10^-4 mol/kg, MW 279.1) of the currently clinic use for cancer therapy. Because of its side effects, treatments by 1x10^-4 and 5x10^-5 mmol/kg of CTX continued for the first 7 days. Each mouse was administrated intraperitoneally (i.p.) a single dose of 0.2 ml per day from the second day of inoculation and continued to the day before sacrifice. The change of the tumor size was precisely measured every 24 hours.

[0052] Two different doses, 1x10^-7 and 2x10^-7 mol/kg of hydrolated metallofullerene nanoparticles, obtained from two independent experiments, have greatly reduced the tumor weights (Table 1) and tumor volumes (Figure 5-8) significantly.

Table 1 Antitumor activity of metallofullerol on murine H22 hepatoma

	Groups Dosage	Tumor weight (g)	Inhibition efficiency (%)	T-test
	Saline (n=7)	3.91±0.78	0
Dosage I	CTX
(low)	(5x10-5 mol/kg/day, n=6)	1.80±0.41	52.0	P<0.01
	Gd@C82(OH)22
	(1x10-7 mol/kg/day, n=5)	2.52±0.74	32.9	P<0.01
	Gd@C82(OH)26
	(1x10-6 mmol/kg/day, N=7)	3.65±1.00	7.7	P>0.01
	Saline (n=5)	3.75±0.87	0
Dosage II	CTX
(high)	(1 x104 mol/kg/day, n=11)	1.22±0.86	67.5	P<0.01
	Gd@C82(OH)22
	(2x10-7 mol/kg/day, n=6)	1.65±1.00	57.7	P<0.01
	Gd@C82(OH)26
	(2x10-3 mmol/kg/day, N=7)	1.05±0.65	72.0	P<0.01

[0053] Table 1 is the tumor weights (mean ± SEM, Table 1) from 5-7 mice in each group. Figure 1 is the Inhibition curve of hepatoma growth in mice by treatment with metallofullerol nanoparticles in two independent experiments. The growth of tumor size was monitored through measuring the diameter of the tumor every 24 hours. Tumor volumes were then calculated according to the formula: V=4πr³/3. Tumor growth curve was obtained by the diameter of the tumor.

[0054] In another aspect, the hydrolated metallofullerene nanoparticles have low toxicity in vivo. Liver function was evaluated with serum levels of total bilirubin levels (TBIL), alanine aminotransferase (ALT) and aspartate aminotransferase (AST). Nephrotoxicity was determined by blood urea nitrogen (BUN) and creatinine (Cr). For instance, the ALT levels of saline-treated groups are almost 4 times of the normal mean value. These indicate that implantation of H22 hepatoma itself in mice has harmed the functions of liver and kidney before treatments. Serum concentrations of TBIL, BUN, and Cr do not significantly changed by i.p. injections of CTX or hydrolated metallofullerene nanoparticles. After nanoparticle-treatment, the activities of ALT and AST (P<0.01) are reduced by 40% compared with saline control. Contrarily, in CTX-treated mice the serum ALT (a more specific and sensitive indicator for evaluating hepatocellular damages than AST) is not reduced, but even slightly increased (Table 2). The results suggest that, unlike CTX, hydrolated metallofullerene nanoparticles can efficiently cease the deterioration of hepatocellular function caused by H22 hepatoma.

[0055] Table 2 is the serum TBIL, ALT, AST, and creatinine levels in tumor-bearing mice associated with metallofullerol treatment.

Table 2 Serum TBIL, ALT, AST, and creatinine levels in tumor-bearing mice associated with metallofullerol treatment

	TBIL	ALT	AST	Creatinine
Groups	(µmol/L)	(IU/L)	(IU/L)	(µmol/L)
Saline	1.54±0.55	146±36.3	888±181	48.8±3.8
CTX-High	1.66±0.59	152.2±71.5	337±53.7a	51.0±3.3
metal lofullerol-High dose	1.44±0.26	87.2±32.0a	234±27.3a	51.4±3.6
Normal mice (n=10)	2.20±0.54	38.3±7.0	142±20.0	55.7±3.0

Note: a represents P<0.01 compared with Saline group

[0056] Very interesting, [Gd@C₈₂(OH)₂₂]_n nanoparticles was observed to greatly enhance immunity and resistibility of tumor-bearing mice. The tumor morphology of HE staining of paraffin-embedded sections of tumor tissues in nanoparticle-treated, CTX-treated and the control groups, are shown in Figure 9. In the saline control group, tumor cells heavily proliferated, arrayed regularly, and grievously invaded surrounding musculature (Figures 9A and B). Treatments of CTX and [Gd@C₈₂(OH)₂₂]_n evidently induced tumor necrosis and hence resulted in the shrinking tumor size (Figures 9D-F). Surprisingly, the strong immune responses were observed in tumor tissues of [Gd@C₈₂(OH)₂₂]_n-treated mice (Figure 9C), but not observed in the CTX-treated and the control groups. When spontaneous H22 liver tumors developed subcutaneously in mice, the envelope surrounding the neoplastic tissues, mainly composed of capillary vessels, fibrosis and lymphadenoid tissues were formed (Figure 9C). Here, host lymphocyte (neutrophil cell mainly) infiltration was observed in fibroblasts and with some tumor cells inside. In the [Gd@Cs₂(OH)₂₂]_n-treated groups, lymphocyte hyperplasia (lymphopoiesis) and aggregated follicles around the transplanted tumor tissues were clearly seen (Figure 9C). But in the CTX-treated mice, this envelope of fibroblasts associated with sporadic neutrophil cells was small so that it could not completely enclose the entire tumor tissues. Unlike in groups of the nanoparticle-treatment, the tumor invasion into surrounding normal muscle cells still existed in the CTX-treatment groups; although necrosis of tumor tissue was observed (Figures 9E and F).

[0057] The histopathological examinations of tissues and organs of the treated mice, which were performed by standard histological techniques with hematoxylin-eosin (HE) staining, revealed that treatment of hydrolated metallofullerene nanoparticles did not produce any abnormally pathological changes on liver, spleen, kidney, heart, brain, and lung tissues.

Example 7

[0058] Athymic BALB/c nu/nu female mice (weighing 16.0±1.0g) were acclimated in the controlled environment (22±1°C in temperature, 60±10% in humidity and a 12 h light/dark cycle) with free access to sterile distilled water and commercial laboratory complete food containing no pathogens. All animal experiments were performed in compliance with local ethics committee. The human beast cancer MCF-7 cell line was provided by the Cancer Institute and Cancer Hospital, Chinese Academy of Medical Sciences. The tumor bearing nude mice (female) were randomly divided into three groups, twelve in each group. In the experimental group, the mice were administered intraperitoneally (i.p.) [Gd@C₈₂(OH)_x]_n saline solution once a day at the dose of 2.5 µmol/kg, after the tumor tissue implantation into the animal for 7 days, continuing until the mice were sacrificed. A currently used clinical antitumor agent, paclitaxel, was used as the positive control. Paclitaxel was given 4 times at intervals of 3 days at the dose of 10 mg/kg; when it was not injected, saline solution was injected instead of it. 0.9% saline solution was used as a negative control in the antitumor experiment. The whole administration process lasted 14 days after the starting point. The body weight and tumor size were used as two basic parameters in the experiments, and tumor growth and body weight curve were prepared as a function of time. Tumor weight was calculated according to the formula: Tumor weight (mg) = length (mm) x (width (mm))²/2.

Table 3 Antitumor activity of Gd@C₈₂(OH)_m on MCF-7 human breast carcinoma in nude mice

Group	Dosage	Inhibition efficiency (%)
Saline	N=8
Gd@C82(OH)32	2.5 µmol/kg/day, N=10	47
Gd@C82(OH)12	1 µmol/kg/day, N=10	35.6
CTX	71.6 µmol/kg/day, N=10	47.0
Pacilitaxel	15.2 µmol/kg/day, N=9	82

(N represents number of mice)

[0059] There was a significant difference in tumor weight under Gd@C₈₂(OH)_x treatment compared with saline treatment. Though the dose of the nanoparticle used was about one third of the paclitaxel, nanoparticle treatment (3.8 mg/kg dose) yielded a similar reduction in tumor weight compared with paclitaxel treatment (10 mg/kg dose). More importantly, the zero mortality of mice with Gd@C₈₂(OH)_x nanoparticle treatment, while 16.7% mortality of mice with paclitaxel treatment were observed. The tumor inhibition results obtained from animal experiments are summarized in Table 3.

Example 8

Activity of La@C₈₂(OH)₁₈ on Lewis lung Carcinoma

[0060] C57B1/6 female mice (6-8 weeks old) were used for the Lewis Lung Carcinoma (LLC) subcutaneous model. The mice were injected subcutaneously in the right leg with 0.2 mL of cell suspension containing 5 × 10⁵ LLC cells (purchased from ATCC. Tumors were allowed to grow for approximately 5 days to a volume of 100 - 200 mm ³ measured using calipers before treatment. Tumor-bearing mice were randomly divided into 3 groups for saline (control), La@C₈₂(OH)₁₈ treatment (1 µmol/kg q.d.×14 days), and CTX (71.6 µmol/kg q.d.×7days), respectively.

[0061] The tumor growth curves are shown in Figure 10. La@C₈₂(OH)₁₈ nanoparticles inhibited the tumor growth significantly, which have the similar efficiency but the concentration is much lower than the clinical drug CTX.

Example 9

Activity of Gd@C₆₀(OH)₂₀ on Lewis lung Carcinoma

[0062] C57B1/6 female mice (6-8 weeks old) were used for the Lewis Lung Carcinoma (LLC) subcutaneous model. The mice were injected subcutaneously in the right leg with 0.2 mL of cell suspension containing 5 x 10⁵ LLC cells (purchased from ATCC. Tumors were allowed to grow for approximately 5 days to a volume of 100-200 mm ³ measured using calipers before treatment. Tumor-bearing mice were randomly divided into 2 groups for saline (control) and Gd@C₆₀(OH)₂₀ treatment (0.5 µmol/kg q.d.×18 days), respectively.

[0063] Gd@C₆₀(OH)₂₀ nanoparticles inhibited the tumor growth significantly. Compared to the saline control, the inhibition ratio reached 42%.

Example 10

Cytotoxicity tests

Methods:

(1) MTT assay for analyzing cell viability after incubation with metallofullerols

[0064] MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] assay is a laboratory test and a standard colorimetric assay for measuring cell viability and cellular proliferation. MTT assay first described by Mosmann in 1983, is based on the ability of a mitochondrial dehydrogenase enzyme from viable cells to cleave the tetrazolium rings of the pale-yellow MTT and form dark-blue formazan crystals, which are largely impermeable to cell membranes, thus resulting in its accumulation within healthy cells.

[0065] Briefly, 5 ml 10⁵ /ml of cells were incubated in a culture flask, 24 h later, the original culture medium was replaced by 5 ml culture medium without serum. Different concentrations of metallofullerols were added into cell medium at various concentrations. After 24 h incubation, 100 µL methylthiazoletetrazolium solution (0.5mg/mL in phosphate buffered saline) was added to each well. The plates were incubated for 3 hours at 37 °C. After the incubation, 100 µL dimethyl sulfoxide was added to each well for 10 minutes at room temperature. Absorbance was measured at 570 nm using a plate reader.

(2) Flow cytometry: propidium iodide (PI) staining for apoptotic cells

[0066] 5 ml 10⁵ /ml of cells were incubated in a culture flask, 24 h later, the original culture medium was replaced by 5 ml culture medium without serum. Different concentrations of metallofullerols were added into cell medium at various concentrations. After 24 h incubation, cells were harvested, washed with physiological saline solution twice, and fixed with 70% ethanol at 4 °C. The cell suspension was supplemented with 25 ppm RNase A and 50 ppm propidium iodide (PI) prior to the measurement, after washing with physiological saline solution twice and suspending. PI would not stain live cells. It would enter dead or late apoptotic cells and incorporate into DNA, thereby selectively staining the dead and late apoptotic cells into red color. The amount of apoptosis cells would be measured by the hypodiploid peak which appeared beside the G1 peak.

Experimental results for cell study:

[0067] 

[1] Treatment of the Human hepatic carcinoma derived cells (HepG2) with 10-10⁶ nmol/L of Gd@C₈₂(OH)₂₂ could not result in the increase of the cell death, as shown in Figure 11.

[2] The ratio of late apoptotic or necrotic cells in the [Gd@C82(OH)22]n-treated HepG2 is 2-4% determined by flow cytometry, which is the same as the control (Figure 12). Thus, the results obtained from both MTT and PI staining indicated no cytotoxicity of [Gd@C82(OH)22]n at the tested concentrations ranging from 10-10⁶ nmol/L.

[3] The ratio of late apoptotic or necrotic cells in the Gd@C₈₂(OH)₂₆ -treated Murine hepatic carcinoma cells (Rh35) is 2-4% determined by flow cytometry, which is the same as the control (Figure 13). Thus, the results indicate that Gd@C₈₂(OH)₂₆ at the tested concentrations ranging from 10-10⁶ nmol/L cannot induce the apoptosis of Rh35 cells.

[4] Cytotoxicity of Gd@C₈₂(OH)₃₂ to human breast cancer cells (MCF-7)by flow cytometry (Figure 14) show that Gd@C₈₂(OH)₃₂ did not induce the apoptosis of MCF-7 cells at the concentration of 10-10⁶ nmol/L. The apoptotic cells are about 3.0%-9%, which are similar to the control. Gd@C₈₂(OH)₃₂ shows nearly no cytotoxicity in cancer cells.

[5] Cytotoxicity of La@C₈₂(OH)₂₀ to human neuro-gliama cells (C6) by MTT (Figure 15) show that La@C₈₂(OH)₂₀ has no influence on cell viability at the final concentration of 100-10⁶ nmol/L, as shown in Figure 15. Cytotoxicity assays using longer exposure times (48-72 hours) also gave similar results, there is no significant difference between La@C₈₂(OH)₂₀ treated cells and control.

[0068] To summarize, the above several metallofullerols show nearly no cytotoxicity in various types of cancer cells, although their hydroxyl numbers and metals are different. Unlike traditional anticancer medicines which are highly cytotoxic and cell killers, metallofullerols nanoparticles do not kill cells obviously and directly.

Claims

1. Metallofullerols for use in inhibition of tumor growth, characterized in that they are represented by general formula M@C_2m(OH)_x, wherein M is a rare earth metal of La or Gd, m=41 or 30 and 10≤x<50.

2. Composition for use in inhibition of tumor growth characterized in that it comprises the metallofullerols nanoparticles represented by [M@C_2m(OH)_x]n_, wherein M is a rare earth metal of La or Gd, m=41 or 30 and 10≤x<50, n is the number of molecules of the metallofullerols from which the metallofullerols nanoparticles are formed by agglomeration, 1≤n<200.

3. The composition for use according to claim 2, characterized in that said composition comprises solvent and/or medicine-compatible carrier.

4. The composition for use according to claim 3, characterized in that said solvent consists of water, physiological saline, Tris-HCl or phosphate buffer.

5. The composition for use according to claim 3 or 4, characterized in that the concentration of the metallofullerols in the composition is 1x10^-5-1 mmol/L.

6. The metallofullerols for use according to claim 1 or the composition for use according to any one of claims 2 to 5, characterized in that said tumor is selected from the group consisting in lung cancer, liver cancer, gastric cancer, esophageal cancer, colorectal carcinoma, bladder cancer, breast cancer, cervical cancer, ovary cancer, human osteosarcoma, angiosarcoma, lymphosarcoma, leucocythemia, melanoma, and skin cancer.

7. Use of a metallofullerol in the preparation of tumor-inhibiting medicine, characterized in that said metallofullerol is represented by general formula M@C_2m(OH)_x, wherein M is a rare earth metal of La or Gd, m=41 or 30 and 10≤x<50.

8. Use of a composition in the preparation of tumor-inhibiting medicine, characterized in that it comprises the metallofullerols nanoparticles represented by [M@C_2m(OH)_x]_n, wherein M is a rare earth metal of La or Gd, m=41 or 30 and 10≤x<50, n is the number of molecules of the metallofullerols from which the metallofullerols nanoparticles are formed by agglomeration, 1 ≤n<200.

9. The use according to claim 7 or 8, characterized in that said tumor-inhibiting medicine are made into different dosage forms, and dose of the metallofullerol is 5x10^-8-1x10^-2 mmol/kg/day.

10. The use according to claim 7 or 8, characterized in that said tumor-inhibiting medicine are made into different dosage forms, and dose of the metallofullerenol is 5x10^-6 1.25x10^-4 mmol/kg/day.

Ansprüche

1. von Metallofullerenen für den Einsatz in der Hemmung von Tumorwachstum, die durch die allgemeine Formel M@C2m(OH) x charakterisiert sind, wobei M eines der Seltenerdmetalle La oder Gd, m = 41 oder 30 und 10 ≤ x <50 ist.

2. der Zusammensetzung von Metallofulleren-Nanopartikel für den Einsatz in der Hemmung des Tumorwachstums, die durch die Allgemeinformel [M@C2m(OH) x] n charakterisiert ist, wobei M das Seltenerdmetall La oder Gd, m = 41 oder 30 und 10 ≤ x <50, sowie n die Anzahl der Moleküle des Metallofullerens ist. Die Metallofulleren-Nanopartikel werden dabei durch Agglomeration mit 1 ≤ n <200 Teilchen gebildet.

3. der Zusammensetzung für die Verwendung nach Anspruch 2. Die Anmeldung umfasst ebenfalls die Anwendung in verschiedenen Lösungsmitteln und / oder in der Medizin-verträglichen Träger.

4. der Zusammensetzung für die Verwendung nach Anspruch 3. Die Anmeldung umfasst ebenfalls die Anwendung von Lösungsmittel aus Wasser, physiologische Kochsalzlösung, Tris-HCl oder PhosphatPuffer.

5. der Zusammensetzung für die Verwendung nach Anspruch 3 oder 4. Die Anmeldung umfasst hier ebenfalls Metallofullerene angewendet in einer Konzentration von 1x10⁵ bis 1 mmol / L.

6. von Metallofullerene für die Verwendung nach Anspruch 1 oder die Zusammensetzung für den Einsatz nach einem der Ansprüche 2-5 gelten für die Behandlung von Tumoren aus folgender Gruppe: Lungenkrebs, Leberkrebs, Magenkrebs, Speiseröhrenkrebs, kolorektalem Karzinom, Blasenkrebs, Brustkrebs, Gebärmutterhalskrebs, Eierstockkrebs, menschliche Osteosarkom, Angiosarkom, Lymphosarkom, Leucocythemia, Melanom und Hautkrebs.

7. der Verwendung eines Metallofullerens bei der Herstellung von Tumor-hemmenden Medikamenten, in dem dieses Metallofullerene durch die allgemeine Formel M@C2m(OH) x gekennzeichnet ist, wobei M eins der Seltenerdmetalle La oder Gd, m = 41 oder 30 und 10 ≤ x <50 ist.

8. für die Verwendung einer Zusammensetzung bei der Herstellung von Tumor-hemmende Medikamenten, die dadurch gekennzeichnet sind, dass Metallofulleren-Nanopartikel charakterisiert durch die Allgemeinformel [M@C2m(OH) x] n, wobei M eines der Seltenerdmetalle La oder Gd, m = 41 oder 30 und 10 ≤ x <50, und n die Anzahl der Moleküle des Metallofullerens ist, bei dem die Metallofulleren-Nanopartikel durch Agglomeration mit 1 ≤ n <200 gebildet werden.

9. für die Verwendung nach Anspruch 7 oder 8, sie umfasst Anwendung tumorhemmender Medikamente in verschiedenen Darreichungsformen, wobei die Dosis der Metallofullerene 5x10⁸-1x10² mmol / kg / Tag ist.

10. für die Verwendung nach Anspruch 7 oder 8, sie umfasst die Anwendung tumorhemmender Medikamente in verschiedenen Darreichungsformen, wobei die Dosis der Metallofullerene 5x10⁶-1.25x10⁴ mmol / kg / Tag ist.

Revendications

1. Les Métallofullérols pour une utilisation dans l'inhibition de la croissance tumorale, sont caractérisés par leur représentation par la formule générale M@C_2m(OH)_x, où M est un métal des terres rares La ou Gd, m=41 ou 30 et 10≤x<50.

2. La composition pour une utilisation dans l'inhibition de la croissance tumorale, est caractérisée par le fait qu'elle comprend les nanoparticules de métallofullérols représentées par [M@C_2m(OH)_x]_n, où M est un métal des terres rares La or Gd, m=41 ou 30 et 10≤x<50 et n est le nombre de molécules de métallofullérols à partir desquelles les nanoparticules de métallofullérols sont formées par agglomération, 1≤n<200.

3. La composition pour l'utilisation décrite dans la déclaration 2, est caractérisée en ce que la dite composition comprend le solvant et/ou le transporteur compatible avec le médicament.

4. La composition pour l'utilisation décrite dans la déclaration 3, est caractérisée en ce que le dit solvant consiste en de l'eau, de l'eau physiologique saline, du Tris-HCl ou du tampon phosphate.

5. La composition pour l'utilisation décrite dans les déclarations 3 ou 4, est caractérisée telle que la concentration des métallofullérols dans la composition est de 1x10^-5 à 1 mmol/L.

6. Les métallofullérols pour l'utilisation selon la déclaration 1 ou la composition pour une utilisation selon une des déclarations 2 à 5, sont caractérisés par le fait que la dite tumeur appartient au groupe composé du cancer du poumon, cancer du foie, cancer gastrique, cancer de l'oesophage, cancer colorectal, cancer de la vessie, cancer du sein, cancer cervical, cancer des ovaires, ostéosarcome humain, angiosarcome, lymphosarcome, leucémie, mélanome et cancer de la peau.

7. Utilisation des métallofullérols dans la préparation d'un médicament inhibiteur de tumeurs, caractérisée par ce que le dit métallofullérol est représenté par la formule générale M@C_2m(OH)_x, où M est un métal des terres rares La ou Gd, m=41 ou 30 et 10≤x<50.

8. Utilisation d'une composition dans la préparation d'un médicament inhibiteur de tumeurs, caractérisée par le fait qu'elle comprend les nanoparticules de métallofullérols représentées par la formule générale [M@C_2m(OH)_x]_n, où M est un métal des terres rares La ou Gd, m=41 ou 30 et 10≤x<50 et n est le nombre de molécules de métallofullérols à partir desquelles les nanoparticules de métallofullérols sont formées par agglomération, 1 ≤n<200.

9. L'utilisation selon les déclarations 7 ou 8, est caractérisée par le fait que les dits médicaments inhibiteur de tumeurs sont préparés selon différentes formes de dosages et la dose de métallofullérols est de 5x10^-8 à 1x10^-2 mmol/kg/jour.

10. L'utilisation selon les déclarations 7 ou 8, est caractérisée par le fait que les dits médicaments inhibiteur de tumeurs sont préparés selon différentes formes de dosages et la dose de métallofullérols est de 5x10^-6 à 1.25x10^-4 mmol/kg/jour.

Drawing